{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:41:25Z","timestamp":1784421685668,"version":"3.55.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Nipocalimab is a newly approved therapeutic agent that modulates a distinct immune transport pathway and has shown considerable promise in treating patients with motor impairment stemming from dysregulated antibody responses. Cleared for use in individuals aged 12 and older, this biology marks a notable advancement in managing many autoimmune conditions, including myasthenia gravis which exists in 150\u2013200 individuals per million. The results of nipocalimab in patients with the latter condition were read in peer-reviewed literature and clinical trial data and key outcomes were extracted. The disease in focus is characterized by fluctuating muscular weakness and reduced endurance due to immune system disruption at the neuromuscular interface. While existing interventions offer some relief, many are limited by side effects or suboptimal long-term control, underscoring the need for better-targeted therapies. Interrupting the mechanism that prolongs the circulation of specific immune proteins presents a refined strategy to lower pathogenic activity while maintaining overall immunological integrity. This compound disrupts the cellular routing system involved in antibody preservation, leading to a selective decline in disease-associated immunoglobulins while leaving protective antibodies largely unaffected. Clinical studies across healthy and affected populations have demonstrated a favorable safety record and meaningful biological responses, including enhanced physical functioning. Late-stage trials have confirmed significant improvements in key health parameters, reinforcing the agent\u2019s therapeutic value. This biology introduces a more precise, well-tolerated, and durable option for treating myasthenia gravis.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004103","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:00:32Z","timestamp":1760342432000},"page":"7891-7893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Nipocalimab: a significant milestone in the treatment of myasthenia gravis approved by the FDA"],"prefix":"10.1097","volume":"87","author":[{"given":"Sonia","family":"Irfan","sequence":"first","affiliation":[{"name":"Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawiya","family":"Sana","sequence":"additional","affiliation":[{"name":"Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-5153","authenticated-orcid":false,"given":"Md Ariful","family":"Haque","sequence":"additional","affiliation":[{"name":"Voice of Doctors Research School, Dhaka, Bangladesh"},{"name":"Department of Public Health, Atish Dipankar University of Science and Technology, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"R3-20260319","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence\u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R4-20260319","doi-asserted-by":"crossref","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front Neurol"},{"key":"R5-20260319","first-page":"1\u20134","article-title":"FcRn inhibitors in the context of myasthenia gravis","volume":"28","author":"Menon","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"R6-20260319","doi-asserted-by":"crossref","first-page":"575\u201391","DOI":"10.1007\/s40120-025-00711-3","article-title":"Risk of exacerbation and level of healthcare resource utilization in myasthenia gravis assessed by myasthenia gravis activities of daily living score","volume":"14","author":"Ting","year":"2025","journal-title":"Neurol Ther"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"MAbs"},{"key":"R8-20260319","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol"},{"key":"R9-20260319","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"R11-20260319","doi-asserted-by":"crossref","first-page":"587\u201399","DOI":"10.1007\/s40261-024-01380-0","article-title":"Pharmacokinetics and pharmacodynamics of nipocalimab, a neonatal Fc receptor blocker, in healthy Japanese volunteers","volume":"44","author":"Matsushima","year":"2024","journal-title":"Clin Drug Investig"},{"key":"R12-20260319","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"R13-20260319","doi-asserted-by":"crossref","first-page":"105\u201316","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:04:47Z","timestamp":1773936287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004103","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"2025-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}